Silencing– tag –
-
Scribe Therapeutics Achieves $129M IPO, Targeting Cardiometabolic Diseases with Reversible Epigenetic Gene Silencing
BioPharma Dive USA Overview Scribe Therapeutics successfully completed a $129 million IPO, marking the first gene editing company to go public in over two years. The company develops an epigenetic approach that silences gene expression w... -
Scribe Therapeutics Files for Nasdaq IPO, Advancing CRISPR-Based Cardiovascular Disease Platform STX-1150 for Hypercholesterolemia
Endpoints News USA Overview Scribe Therapeutics, co-founded by Nobel laureate Dr. Jennifer Doudna, has filed for an initial public offering (IPO) on Nasdaq. This move signals a crucial strategy for the company to expand its CRISPR-based ...
1